Pharmathene

Last week was another volatile one for investors. Among the ten biggest losers were a wheel maker, a photography pioneer, and a fast-growing mobile apps maker. Recognize any stocks you own there? Read on to find out what went wrong with these companies.

Two biotechs, SIGA and PharmAthene, vying to establish a foothold in the potentially vast biodefense market are in the midst of duking it out in a multibillion dollar legal battle. The crux of the dispute is a smallpox vaccine being developed for the military.

Some of Monday's best online stories for investors: Why Steve Jobs is a success; how Pharmathene could go from $2 to $20; and why Twitter is massively undervalued when compared with Facebook.